2nd Scientific Advice Meeting

As discussed during the first Scientific Advice Meeting in April 2014 with Swissmedic, the regulatory authority of Switzerland, the TargetAMD consortium adopted the protocols for scheduled in vivo safety studies and the procedure for the clinical trial in Geneva, respectively. These protocols will now present and discussed at Swissmedic during a second Scientific Advice Meeting probably taking place in March 2015.

5. February 2015
Categories: Target AMD